HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

Social media ‘tears down walls’ in medicine

Point/Counter

Is social media a ‘slippery slope’ in medicine that should be avoided?

Editorial

Access to cancer clinical trials may not entirely level the playing field

John Sweetenham, MD

Molecular Oncology

Precision oncology: Exciting clinical developments and complicated biology

Wafik S. El-Deiry, MD, PhD, FACP

Feature

Poor air quality linked to hospitalizations among childhood cancer survivors

Meeting News

Radiation improves outcomes with pembrolizumab for metastatic lung cancer

Low PSA levels predict lack of benefit from long-term hormone therapy after prostate surgery

Patients with lung cancer lack knowledge of clinical trials

Plasma tumor mutational burden predicts outcomes with first-line pembrolizumab for metastatic NSCLC

Researchers identify mutations associated with treatment sensitivity, resistance in NSCLC

Association of Community Cancer Centers announces award recipients

International Association for the Study of Lung Cancer announces president-elect, board members

In the Journals

Cancer screening rates ‘unexpectedly high’ among adults aged 85 years and older

High-volume, NCI-designated centers not associated with greater value in pancreatic cancer care

Extended edoxaban, dalteparin equally effective among patients with cancer, venous thromboembolism

Six prognostic factors identified for invasive breast cancer recurrence after DCIS

FDA News

FDA grants priority review to crizanlizumab for pain crises in sickle cell disease

FDA approves Xpovio regimen for patients with relapsed or refractory multiple myeloma

FDA grants fast track designation to CLR 131 for diffuse large B-cell lymphoma

FDA grants breakthrough therapy designation to capmatinib for lung cancer subset

$9 million grant funds trial of CAR T-cell therapy for metastatic breast cancer